ArticleCancers2023

Blood-Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study.

Hanne K Kuitunen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.